Breaking Finance News

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Having a price of $4.53, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) traded -1.94% lower on the day. With the last close down -11.55% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.04% over the same period. SPPI has recorded a 50-day average of $4.38 and a two hundred day average of $5.14. Trade Volume was down over the average, with 571,360 shares of SPPI changing hands under the typical 765,557

Zacks Investment Research has downgraded Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to Sell in a statement released on 1/11/2017.

On Tuesday February 16, 2016, Jefferies & Co released a statement on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) dropped the target price from $6.00 to $5.00 that suggested an upside of 0.13%.

Recent Performance Chart

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. has with a one year low of $3.21 and a one year high of $7.74 and has a market capitalization of $0.

General Company Details For Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin's lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.